A. Amelsberg

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Andrew M. Scott, G. Wiseman, Sydney Welt et al. · PubMed · 2003 · 442 citations

Medicine, Oncology, Pharmacology +17

Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer

Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Frank Hartmann et al. · Oncology Research and Treatment · 2003 · 366 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

F. Eskens, Constantijne H. Mom, André Planting et al. · British Journal of Cancer · 2007 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

Ch. Dittrich, G. Greim, Markus Borner et al. · European Journal of Cancer · 2002 · 71 citations

Medicine, Pharmacokinetics, Pharmacology +8

Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients

Charlotte Kloft, E-U. Graefe, P. Tanswell et al. · Investigational New Drugs · 2003 · 62 citations

Pharmacy, Pharmacokinetics, Pharmacology +16